I don't usually post about all the latest advancements in lymphoma research, mostly because I don't keep up with it so much anymore (it seem's I got a little burned out doing so much of it early on), but also because there just hasn't been anything I considered to be of note. This year though, seems to be different. I've started doing a little more reading and investigating of some of the latest happenings in lymphoma/leukemia research, and while there still isn't much I'm encouraged about (anything that is truly interesting is still in early development or clinical trials), there were three reports I thought worth mentioning. The first one was a phase 3 trial, showing that Maintenance Rituximab to be no better than Rituximab administered upon disease progression . While this may not seem so earth shattering to some, I think any research proving less is better, i.e. reducing the number and frequency of treatments, can only be beneficial, and lead to a bette...
The ramblings of a mantle cell lymphoma and bypass surgery survivor, and then some